Active	Status	Sponsor type	Region	Phase	Filter
12 Active 3 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nickerson, Peter
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
Carroll, Robert
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects	Recruiting	2	18	Europe, US, RoW	HM15912 Active, Placebo	Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.	Short Bowel Syndrome	12/27	05/28
REINFUSE, NCT04577456: Chyme Reinfusion for Type 2 Intestinal Failure	Recruiting	N/A	40	Europe, US	The Insides System	Databean, The Insides Company	Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma	03/25	03/25
Wiebe, Chris
No trials found
Gibson, Ian
No trials found
Lesyk, Michelle
No trials found